Latest news with #AlembicPharmaceuticals'
&w=3840&q=100)
Business Standard
3 days ago
- Business
- Business Standard
Why is Alembic Pharmaceuticals' share in demand today? Key details here
Alembic Pharmaceuticals share price: Pharmaceutical major Alembic Pharmaceuticals share price skyrocketed up to 13.98 per cent to hit an intraday high of 1,107.80 per share on Monday, June 30, 2025. Around 12:15 PM, Alembic Pharmaceuticals shares continued to trade near day's high, up 13.34 per cent at 1,101.45 per share. In comparison, BSE Sensex was trading 0.20 per cent lower at 83,892.01 levels. What triggered the rally in Alembic Pharmaceuticals share price today? Alembic Pharmaceuticals' share price surged after the company received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection in two dosage strengths — 20 mg/10 mL and 50 mg/25 mL single-dose vials. The approved product is a therapeutic equivalent of Doxil Liposome Injection by Baxter Healthcare Corporation, and is used in the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma. As per IQVIA, the drug has an estimated market size of around $29 million for the 12 months ending March 2025. With this approval, Alembic Pharmaceuticals now holds a total of 224 ANDA approvals from the USFDA, including 201 final and 23 tentative approvals. Alembic Pharmaceuticals Q4 results Alembic Pharmaceuticals reported a 12 per cent year-on-year (Y-o-Y) decline in net profit for the fourth quarter of FY25 (Q4FY25), which stood at ₹157 crore, despite a 17 per cent rise in net sales to ₹1,770 crore. Ebitda grew 9 per cent to ₹286 crore, with the margin at 16 per cent, while profit before tax increased 5 per cent to ₹192 crore. READ MORE About Alembic Pharmaceuticals Alembic Pharmaceuticals is among the leading Indian pharmaceutical companies with a legacy dating back to 1907. Headquartered in Vadodara, Gujarat, the company has built a strong global presence through its vertically integrated operations that span research, development, manufacturing, and marketing of pharmaceutical products. It is publicly listed and is known for its robust pipeline of generic drugs, backed by advanced R&D infrastructure and regulatory approvals from key markets, including the USFDA. With manufacturing units located in Gujarat and Sikkim, and R&D centres across Vadodara, Hyderabad, and New Jersey, Alembic Pharmaceuticals serves both domestic and international markets. Its subsidiaries, Alembic Pharmaceuticals Inc. and Alembic Global Holding SA, further support its global footprint, making it a trusted name in both branded and generic pharmaceuticals worldwide.
Business Upturn
06-05-2025
- Business
- Business Upturn
Alembic Pharmaceuticals shares drop 2% as Q4 net profit falls 11.9% YoY to Rs 156.89 crore
Alembic Pharmaceuticals saw a dip of over 2% in its shares following the announcement of Q4FY25 results. As of 2:08 PM, the shares were trading 1.94% down at Rs 887.85. Despite this, the company reported a solid 17% year-on-year (YoY) growth in consolidated net revenue, reaching ₹1,769.64 crore, up from ₹1,516.98 crore in Q4FY24. However, net profit for the quarter decreased slightly to ₹156.89 crore from ₹178.21 crore YoY, primarily due to higher expenses. This, however, represented an improvement over the ₹138.42 crore reported in Q3FY25. For the full financial year FY25, Alembic posted total revenue of ₹6,714.63 crore, a 7% increase from ₹6,256.93 crore in FY24. Net profit for FY25 stood at ₹583.42 crore, down marginally from ₹615.82 crore YoY, impacted by higher operating costs and tax provisions. The company's performance across its segments was strong: the domestic India business grew by 8% YoY to ₹545 crore, the US generics segment surged 20% YoY to ₹508 crore, and Ex-US generics grew 43% YoY, reaching ₹375 crore. The API segment showed a steady 4% YoY growth, contributing ₹342 crore. EBITDA for the quarter increased by 9% YoY to ₹286 crore, with an EBITDA margin of 16%. Profit before tax stood at ₹191.95 crore, up from ₹182.85 crore in Q4FY24, reflecting solid operational efficiency. Alembic Pharmaceuticals' shares opened at ₹913.50 and reached a high of ₹913.50, with a low of ₹880.60. The stock is currently trading below its 52-week high of ₹1,303.90 and above its 52-week low of ₹725.20. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
